Key result
Heart failure biomarkers such as natriuretic peptides, troponins, and sST2 offer potential for diagnostic and risk stratification in hemodialysis patients, though optimal cut-offs remain undefined.
Why the study?
End-stage renal disease significantly raises cardiovascular risk and death, with heart failure and arrhythmias being major causes, prompting the need to assess heart failure biomarkers for cardiovascular risk assessment.
Heart failure biomarkers provide valuable prognostic information in hemodialysis patients, though interpretation must account for renal clearance and dialysis effects.
Supports CV risk stratification in ESRD; leaves open targeted interventions pending prospective data.
The diagnosis of end-stage renal disease (ESRD) is made when the estimated glomerular filtration rate is less than 15 mL/min/1.73 m2. Most patients with that stage of chronic kidney disease (CKD) are eligible for renal replacement treatment, which includes kidney transplantation, hemodialysis and peritoneal dialysis. It is well recognized that CKD raises the risk of cardiovascular disease and is linked to a higher cardiovascular death rate in this population. Additionally, the largest risk of cardiovascular events is seen in ESRD patients. Heart failure (HF) and dangerous arrhythmias, which are more common in the advanced stages of CKD, are two additional causes of cardiovascular death in addition to atherosclerosis-related complications such as myocardial infarction and stroke. In this review the significance of natriuretic peptides and other HF biomarkers in hemodialysis patients, as tools for cardiovascular risk assessment will be discussed.
No takes yet. Share an insight, caveat, or question.
Heleniak et al. (2024) conducted a review in End-stage renal disease on hemodialysis. Heart failure biomarkers (NPs, Troponin, sST2, Galectin-3, GDF15, H-FABP) was evaluated. Heart failure biomarkers such as natriuretic peptides, troponins, and sST2 offer potential for diagnostic and risk stratification in hemodialysis patients, though optimal cut-offs remain undefined.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: